A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003495-200565030-00003PMID 15669878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin Aspart

  2012cited by this paper
• Insulin Glargine

  2012cited by this paper
• Insulin Aspart

  2012cited by this paper
• Insulin Detemir

  2012cited by this paper
• Insulin Lispro

  2012cited by this paper
• Insulin Glargine

  2012cited by this paper
• Drug Therapy of Postprandial Hyperglycaemia

  2012cited by this paper
• Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.

  2006cited by this paper
• Clinical Practice Recommendations 2005.

  2005cited by this paper
• Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.

  2004cited by this paper
• Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.

  2004cited by this paper
• Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine.

  2004cited by this paper
• Standards of medical care in diabetes.

  2004cited by this paper
• Insulin glargine: long-acting basal insulin analog for improved metabolic control

  2004cited by this paper
• Insulin analogues in the management of diabetes.

  2004cited by this paper
• Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study.

  2004cited by this paper
• Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

  2004cited by this paper
• Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.

  2004cited by this paper
• The safety and efficacy of insulin analogs in pregnancy

  2004cited by this paper
• Insulin storage in Europe: a comment to Grajower et al., Eli Lilly, and Novo Nordisk.

  2004cited by this paper
• At last, a weight neutral insulin?

  2004cited by this paper
• Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.

  2003cited by this paper
• Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes.

  2003cited by this paper
• Insulin glargine: a systematic review of a long-acting insulin analogue.

  2003cited by this paper
• Perioperative management of type 1 diabetes mellitus.

  2003cited by this paper
• How long should insulin be used once a vial is started?

  2003cited by this paper
• A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes.

  2003cited by this paper
• Effect of the rapid‐acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes

  2003cited by this paper
• Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

  2003cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.

  2003cited by this paper
• A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.

  2003cited by this paper
• A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1.

  2003cited by this paper
• [LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective action.

  2003cited by this paper
• Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus.

  2003cited by this paper
• The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change.

  2003cited by this paper
• The human insulin analogue aspart is not the almighty solution for insulin allergy.

  2003cited by this paper
• Clinical significance, pathogenesis, and management of postprandial hyperglycemia.

  2003cited by this paper
• Effects of Rapid-Acting Insulin Analogs on Overall Glycemic Control in Type 1 and Type 2 Diabetes Mellitus

  2003cited by this paper
• Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.

  2003cited by this paper
• Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus.

  2003cited by this paper
• Glargine insulin is not an alternative in insulin allergy.

  2003cited by this paper
• Insulin glulisine. Aventis Pharma.

  2003cited by this paper
• Insulin glulisine is a novel, parenteral, human insulin analog with a rapid-acting time-action profile A crossover, euglycemic clamp study in normoglycemic dogs

  2003cited by this paper
• Ellenberg and Rifkin's Diabetes Mellitus

  2002cited by this paper
• Evaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and Mice

  2002cited by this paper
• Novel insulins: expanding options in diabetes management.

  2002cited by this paper
• Evaluation of the Reproductive Toxicity and Embryotoxicity of Insulin Glargine (LANTUS) in Rats and Rabbits

  2002cited by this paper
• Oral Insulin Product Hexyl-Insulin Monoconjugate 2 (HIM2) in Type 1 Diabetes Mellitus: The Glucose Stabilization Effects of HIM2

  2002cited by this paper
• Insulin analogues. A critical review.

  2002cited by this paper
• Development of oral insulin: progress and current status

  2002cited by this paper
• Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.

  2002cited by this paper
• Advances in the treatment of diabetes-insulin analogues.

  2002cited by this paper
• A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.

  2002cited by this paper
• New horizons — alternative routes for insulin therapy

  2002cited by this paper
• Drug Therapy: Current and Emerging Agents

  2002cited by this paper
• Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus

  2001cited by this paper
• Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.

  2001cited by this paper
• Intensive insulin therapy in critically ill patients.

  2001cited by this paper
• Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes.

  2001cited by this paper
• Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.

  2001cited by this paper
• Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study.

  2001cited by this paper
• Recombinant DNA technology in the treatment of diabetes: insulin analogs.

  2001cited by this paper
• Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.

  2001cited by this paper
• Treating diabetes with aerosolized insulin.

  2001cited by this paper
• The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes.

  2001cited by this paper
• A Rational Approach to Drug Therapy of Type 2 Diabetes Mellitus

  2000cited by this paper
• Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

  2000cited by this paper
• Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

  2000cited by this paper
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

  2000cited by this paper
• Insulin aspart. Commentaries

  1999cited by this paper
• Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304

  1999cited by this paper
• Is insulin resistance the principal cause of type 2 diabetes?

  1999cited by this paper
• Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients.

  1999cited by this paper
• Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

  1999cited by this paper
• Long-acting insulin analogs.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

  1998cited by this paper
• Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Effectiveness of postprandial Humalog in toddlers with diabetes.

  1997cited by this paper
• Case-control study of sudden infant death syndrome in Scotland, 1992-5

  1997cited by this paper
• Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment

  1997cited by this paper
• Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes

  1997cited by this paper
• Role of the IGF-I receptor in mutagenesis and tumor promotion.

  1997cited by this paper
• Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

  1997cited by this paper
• Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs

  1996cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Albumin binding and time action of acylated insulins in various species.

  1996cited by this paper
• U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

  1995cited by this paper
• The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

  1994cited by this paper
• [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin

  1994cited by this paper
• Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Clinical Pharmacology of Human Insulin

  1993cited by this paper
• Goodman and Gillman's The Pharmacological Basis of Therapeutics

  1992cited by this paper
• A superactive insulin: [B10-aspartic acid]insulin(human).

  1987cited by this paper
• Diabetes in old age

  1986cited by this paper

• Overview of Peptides and Their Potential Roles in Skin Health and Beauty

  2025cites this paper
• Take an individualized and multipronged approach when managing older adults with type 2 diabetes

  2023cites this paper
• Dynamic Detection of HbA1c Using a Silicon Nanowire Field Effect Tube Biosensor

  2022cites this paper
• Structure and properties of insulin

  2022cites this paper
• Advances in FGFs for diabetes care applications.

  2022cites this paper
• Análogos de la insulina. ¿Cuál es su lugar en la terapéutica?

  2022cites this paper
• Management of Hyperglycemia in Older Adults with Type 2 Diabetes

  2021cites this paper
• Assessment of Insulin-related Knowledge among Healthcare Professionals in a Large Teaching Hospital in the United Kingdom

  2019cites this paper
• Evidence-Based Management of Diabetes in Older Adults

  2018cites this paper
• Comparative efficacy and safety of insulin analogs in hospitalized adults.

  2015cites this paper
• Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?

  2015cites this paper
• Proinsulin C-peptide potentiates the inhibitory action of insulin on glucose synthesis in primary cultured rabbit kidney-cortex tubules: metabolic studies.

  2014cites this paper
• AKT question relating to the General Medical Council guidance

  2013cites this paper
• Novel approaches in control of energy and glucose homeostasis in T 2 DM : Glucagon-like Peptide 1 Analogs : Glucagon

  2013cites this paper
• Premixed Insulin Analogues for the Treatment of Diabetes Mellitus

  2012influential citation
• RAPID ACTING INSULIN ANALOGUES

  2012cites this paper
• Insulin Lispro

  2012cites this paper
• Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

  2012cites this paper
• Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus – A pilot study

  2012cites this paper
• Análogos de insulina: relevancia clínica y perspectivas futuras Insulin analogues: clinical relevance and future perspectives

  2012cites this paper
• Early Insulin Initiation—A Review of the Literature and Case Studies

  2012cites this paper
• Diabetes Mellitus in Older Adults

  2012influential citation
• Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Action than Subcutaneous Injection

  2011cites this paper
• Special Considerations with Insulin Therapy in Older Adults with Diabetes Mellitus

  2011cites this paper
• Insulin therapy

  2011cites this paper
• Economics of Insulin Device vs Conventional Vial and Syringe

  2010cites this paper
• Assessment of adherence and healthcare costs of insulin device (FlexPen®) versus conventional vial/syringe

  2010cites this paper
• The effect of healthcare provider education on diabetes management of hospitalised patients

  2010cites this paper
• Translating clinical guidelines into clinical practice: role of the pharmacist in type 2 diabetes management.

  2009cites this paper
• Consequences of Delaying Progression to Optimal Therapy in Patients with Type 2 Diabetes Not Achieving Glycemic Goals

  2009cites this paper
• [Update on new insulins].

  2009cites this paper
• Glycemic control and surgery-optimizing outcomes for the patient with diabetes.

  2009cites this paper
• Insulin analogues: an example of applied medical science

  2009cites this paper
• NEW THERAPEUTIC APPROACHES IN TYPE 2 DIABETES

  2008cites this paper
• Newer Insulins in Search of a Niche

  2008cites this paper
• Insulin and antidiabetic drugs--implications for the perioperative setting.

  2008cites this paper
• Reaching glycaemic targets while minimizing hypoglycaemia in insulin‐treated type 2 diabetes patients

  2008cites this paper
• Insulin therapy in renal disease

  2008cites this paper
• [Insulin therapy for type 1 diabetes mellitus: past and present].

  2008cites this paper
• Insulin Analogues with Increased Mitogenic Potency – Are they Safe?

  2008cites this paper
• Insulin treatment in type 2 diabetes

  2008cites this paper
• Lipodystrophy Reactions to Insulin

  2007cites this paper
• Management of Diabetes-related Hypoglycemia

  2007cites this paper
• pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.

  2007cites this paper
• The treat-to-target A1C approach to control type 2 diabetes and prevent complications

  2007cites this paper
• Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.

  2007cites this paper
• Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes.

  2007cites this paper
• Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs.

  2007cites this paper
• Insulin structure and function.

  2007cites this paper
• The influence of detemir - a long acting analogue of insulin - on the metabolic homeostasis of diabetic patients. Observational study

  2007cites this paper
• The Rate of Improvement in Metabolic Control in Children with Diabetes Mellitus Type 1 on Insulin Glargine Depends on Age

  2007cites this paper
• Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.

  2007cites this paper
• Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues

  2007cites this paper
• Narrative Review: A Rational Approach to Starting Insulin Therapy

  2006cites this paper
• Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes

  2006cites this paper
• Insulin and antidiabetic agents -- the old and the new.

  2006cites this paper
• Case study: lessons learned in the care of a 63-year-old woman with type 2 diabetes.

  2005cites this paper
• Diabetes in overweight pediatric patients.

  2005cites this paper
• Strategies for Testing Long-Term Transcutaneous Amperometric Glucose Sensors

  2005cites this paper
• [Are "designer" insulins the "best" insulins?].

  2005cites this paper